Targeting developmental pathways in children with cancer: What price success?

The Lancet Oncology

Volumn 14, Issue 2, 2013, Pages

  Gore, Lia ^a,b,c   DeGregori, James ^b,c   Porter, Christopher C ^a,b  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b Children's Hospital Colorado   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CIXUTUMUMAB; CRIZOTINIB; DASATINIB; ERLOTINIB; EVEROLIMUS; IMATINIB; IMMUNOGLOBULIN; OLAPARIB; RAPAMYCIN; RITUXIMAB; SORAFENIB; SUNITINIB; VISMODEGIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALOPECIA; ALTERED NEURAL DEVELOPMENT; ANAPHYLAXIS; AZOOSPERMIA; BLEEDING; BONE GROWTH; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CYTOPENIA; DELAYED GROWTH; DEVELOPMENTAL DISORDER; DNA DAMAGE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; GROWTH DISORDER; HEALING IMPAIRMENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGONADISM; HYPOTHYROIDISM; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOGLOBULIN DEFICIENCY; MUSCLE SPASM; MYELOID LEUKEMIA; NEUROBLASTOMA; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; NEOPLASMS;

EID: 84873809412     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70530-2     Document Type: Review

References (75)

1. Weinstein IB Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297:63-64.
2. Kantarjian H, O'Brien S, Garcia-Manero G, et al. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer 2012, 118:3116-3122.
3. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009, 27:5175-5181.
4. Luo J, Solimini NL, Elledge SJ Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
5. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
6. Brenner JC, Feng FY, Han S, et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res 2012, 72:1608-1613.
7. Casa-Selves M, Kim J, Zhang Y, et al. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res 2012, 72:4154-4164.
8. Porter CC, Kim J, Fosmire S, et al. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia 2012, 26:1266-1276.
9. Gregory MA, Phang TL, Neviani P, et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 2010, 18:74-87.
10. Whitehurst AW, Bodemann BO, Cardenas J, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007, 446:815-819.
11. Grunewald TG, Greulich N, Kontny U, et al. Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature. Klin Padiatr 2012, 224:124-131.
12. Moore SW Developmental genes and cancer in children. Pediatr Blood Cancer 2009, 52:755-760.
13. Shah N, Sukumar S The Hox genes and their roles in oncogenesis. Nat Rev Cancer 2010, 10:361-371.
14. McGonigle GJ, Lappin TR, Thompson A Grappling with the HOX network in hematopoiesis and leukemia. Front Biosci 2008, 13:4297-4308.
15. Raffel C, Jenkins RB, Frederick L, et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997, 57:842-845.
16. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002, 31:306-310.
17. Low JA, de Sauvage FJ Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 2010, 28:5321-5326.
18. Kimura H, Ng JM, Curran T Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell 2008, 13:249-260.
19. Pulford K, Lamant L, Espinos E, et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci 2004, 61:2939-2953.
20. Carpenter EL, Mosse YP Targeting ALK in neuroblastoma-preclinical and clinical advancements. Nat Rev Clin Oncol 2012, 9:391-399.
21. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008, 8:11-23.
22. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355:1572-1582.
23. Niraula S, Seruga B, Ocana A, et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 2012, 30:3012-3019.
24. Li T, Perez-Soler R Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009, 4:107-119.
25. Schuster C, Eikesdal HP, Puntervoll H, et al. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One 2012, 7:e38364.
26. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007, 13:3913-3921.
27. Chen HX, Cleck JN Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009, 6:465-477.
28. Yuen JS, Macaulay VM Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 2008, 12:589-603.
29. Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 2011, 159:676-681.
30. Bansal D, Shava U, Varma N, Trehan A, Marwaha RK Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer 2012, 59:481-484.
31. Vandyke K, Dewar AL, Fitter S, et al. Imatinib mesylate causes growth plate closure in vivo. Leukemia 2009, 23:2155-2159.
32. Hobernicht SL, Schweiger B, Zeitler P, Wang M, Hunger SP Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. Pediatr Blood Cancer 2011, 56:671-673.
33. Byrne J, Mulvihill JJ, Myers MH, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med 1987, 317:1315-1321.
34. Apperley J CML in pregnancy and childhood. Best Pract Res Clin Haematol 2009, 22:455-474.
35. Seshadri T, Seymour JF, McArthur GA Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med 2004, 351:2134-2135.
36. Mariani S, Basciani S, Fabbri A, et al. Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. Fertil Steril 2011, 95:1120.
37. Weickhardt AJ, Rothman MS, Salian-Mehta S, et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 2012, 118:5302-5309.
38. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009, 6:219-228.
39. Greaves M Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 2006, 6:193-203.
40. Smith S, Schiffman G, Karayalcin G, Bonagura V Immunodeficiency in long-term survivors of acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster therapy. J Pediatr 1995, 127:68-75.
41. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010, 363:1801-1811.
42. Dancey J mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010, 7:209-219.
43. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
44. Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 2010, 28:3115-3121.
45. Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006, 91:496-502.
46. Irie E, Shirota Y, Suzuki C, et al. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol 2010, 91:501-508.
47. Walker AR, Kleiner A, Rich L, et al. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest 2008, 26:431-433.
48. Wolach O, Bairey O, Lahav M Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010, 89:308-318.
49. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
50. Molina TJ, Kishihara K, Siderovski DP, et al. Profound block in thymocyte development in mice lacking p56lck. Nature 1992, 357:161-164.
51. Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008, 111:1366-1377.
52. Sillaber C, Herrmann H, Bennett K, et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest 2009, 39:1098-1109.
53. Blake SJ, Hughes TP, Lyons AB Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A. Exp Hematol 2012, 40:612-621.
54. Super HJ, McCabe NR, Thirman MJ, et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 1993, 82:3705-3711.
55. DeGregori J Evolved tumor suppression: why are we so good at not getting cancer?. Cancer Res 2011, 71:3739-3744.
56. Gatenby RA, Gillies RJ A microenvironmental model of carcinogenesis. Nat Rev Cancer 2008, 8:56-61.
57. DeGregori J Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age?. Oncogene 2012, published online July 2. 10.1038/onc.2012.281.
58. Bumm T, Muller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003, 101:1941-1949.
59. De Melo VA, Milojkovic D, Khorashad JS, et al. Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia. Blood 2007, 110:3086-3087.
60. Deininger MW, Cortes J, Paquette R, et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer 2007, 110:1509-1519.
61. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006, 108:2811-2813.
62. Pui CH, Relling MV Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 2000, 109:13-23.
63. Libura J, Slater DJ, Felix CA, Richardson C Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion. Blood 2005, 105:2124-2131.
64. Porter CC, Baturin D, Choudhary R, Degregori J Relative fitness of hematopoietic progenitors influences leukemia progression. Leukemia 2011, 25:891-895.
65. Fayad L, Kantarjian H, O'Brien S, et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 1997, 11:767-771.
66. Adjei AA What is the right dose? The elusive optimal biologic dose in phase I clinical trials. J Clin Oncol 2006, 24:4054-4055.
67. Ratain MJ, Glassman RH Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?. Clin Cancer Res 2007, 13:6545-6548.
68. Baselga J, Arteaga CL Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005, 23:2445-2459.
69. Gillies RJ, Verduzco D, Gatenby RA Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012, 12:487-493.
70. Horton TM, Sposto R, Brown P, et al. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer 2010, 54:872-878.
71. Rubin EH, Gilliland DG Drug development and clinical trials-the path to an approved cancer drug. Nat Rev Clin Oncol 2012, 9:215-222.
72. Sharma MR, Stadler WM, Ratain MJ Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst 2011, 103:1093-1100.
73. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997, 89:1138-1147.
74. Rodon J, Saura C, Dienstmann R, et al. Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol 2012, 9:359-366.
75. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011, 19:1079-1095.